Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Net Margin (2016 - 2025)

Historic Net Margin for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to 7.53%.

  • Ptc Therapeutics' Net Margin rose 617300.0% to 7.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.25%, marking a year-over-year increase of 1057300.0%. This contributed to the annual value of 45.03% for FY2024, which is 217800.0% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Net Margin stood at 7.53%, which was up 617300.0% from 36.25% recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Net Margin peaked at 73.68% during Q1 2025, and registered a low of 109.07% during Q1 2021.
  • Its 5-year average for Net Margin is 60.07%, with a median of 65.35% in 2023.
  • The largest annual percentage gain for Ptc Therapeutics' Net Margin in the last 5 years was 1396800bps (2021), contrasted with its biggest fall of -374500bps (2021).
  • Over the past 5 years, Ptc Therapeutics' Net Margin (Quarter) stood at 86.71% in 2021, then dropped by -18bps to 102.08% in 2022, then skyrocketed by 50bps to 50.74% in 2023, then soared by 39bps to 30.91% in 2024, then skyrocketed by 124bps to 7.53% in 2025.
  • Its last three reported values are 7.53% in Q3 2025, 36.25% for Q2 2025, and 73.68% during Q1 2025.